All In Biotech

Drug Trial Radar · NCT01594515

Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 1015550 in Healthy Male Volunteers

Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 1015550 in Healthy Male Volunteers (a Partially Randomised, Partially Single-blind, Placebo-controlled Phase I Study)

Last checked: Nov 19, 2026Latest source record: Dec 15, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

70

Actual

Start

May 2012

Primary completion

Sep 2012

Study completion Sep 2012

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
May 9, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Single
Primary purpose
Treatment
Who can join
Male only, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

In this first-in-man trial, safety, tolerability, pharmacokinetics, and selected pharmacodynamics parameters of BI 1015550 will be assessed in healthy male volunteers.

Conditions

  • Healthy

Interventions

  • BI 1015550Drug

    High dose powder for oral solution

  • BI 1015550Drug

    Medium dose powder for oral solution

  • BI 1015550Drug

    Low dose powder for oral solution

  • BI 1015550Drug

    Low dose powder for oral solution

  • BI 1015550Drug

    Low dose powder for oral solution

  • PlaceboDrug

    Solution for oral administration

  • BI 101550Drug

    High dose powder for oral solution

  • BI 1015550Drug

    Low dose powder for oral solution

  • BI 1015550Drug

    Medium dose powder for oral solution

  • BI 1015550Drug

    Medium dose powder for oral solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number (%) of Subjects With Drug Related Adverse EventsTime frame: From the day of informed consent(-21 days) until the end-of-study examination(within 5 to 7 days after last PK sampling), upto 10 days.
  2. Number (%) of Subjects With Clinically Relevant Abnormalities in Clinical Laboratory TestsTime frame: Day -21 to -2, upto -72 hours, 4h, 24h, 48h, 72h and study examination(within 5 to 7 days after last PK sampling).
  3. Number (%) of Subjects With Clinically Relevant Abnormalities in Vital SignsTime frame: Day -21 to -2, -1 hour, 0.5h, 1h, 2h, 4h, 8h, 10h, 24h, 48h, 72h and study examination(within 5 to 7 days after last PK sampling).
  4. Number (%) of Subjects With Clinically Relevant Abnormalities in 12-lead ECGsTime frame: Day -21 to -2, -1 hour, 0.5h, 1h, 2h, 4h, 8h, 10h, 24h, 48h, 72h and study examination(within 5 to 7 days after last PK sampling).
  5. Number (%) of Subjects With Clinically Relevant Abnormalities in TolerabilityTime frame: From the day of informed consent(-21 days) until the end-of-study examination(within 5 to 7 days after last PK sampling), upto 10 days.
  6. Number (%) of Subjects With Clinically Relevant Abnormalities in Physical ExaminationsTime frame: From the day of informed consent(-21 days) until the end-of-study examination(within 5 to 7 days after last PK sampling), upto 10 days.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • 1305.1.1 Boehringer Ingelheim Investigational Site

    Ingelheim, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.